LOS ANGELES--(BUSINESS WIRE)--
Lion Biotechnologies, Inc. (OTCQB: LBIO) announced that Chief Executive
Officer Manish Singh, Ph.D., will preside over the introductory session
of the Phacilitate Immunotherapy Forum on Monday, January 27, 2014.
Titled “Overviewing key trends in immunotherapy R&D investment,
collaboration and pipeline strategies,” the session will include
presentations by executives from biotechnology and pharmaceutical
companies, and a panel discussion with life science industry and venture
In addition, Lion Biotechnologies’ Vice President, Product Development
and Manufacturing, James G. Bender, Ph.D., will be a panelist in a key
breakfast briefing titled “Development by design – a model for
managing comparability risks and optimizing process development for Cell
Therapy and Immunotherapy processes,” on Wednesday, January 29.
The Immunotherapy Forum is being held January 27-29 at The Grand Hyatt
Hotel in Washington D.C., and is part of Phacilitate’s Washington
Bioleaders 2014 Conference.
“We are pleased to have an important role in this year’s Immunotherapy
Forum, which will have an audience of 500-600 executives from the pharma
and biotech industries, as well as key external stakeholders, including
the world's regulators, public and private sector investors, NGOs,
payers and analysts,” said Dr. Singh. “The conference provides an
excellent opportunity to network with leaders from industry, government
and the investment community, and discuss recent progress in our T-cell
About Lion Biotechnologies
Lion Biotechnologies, Inc. is engaged in the development of T-cells and
engineered T-cells for the treatment of various cancers. The company's
lead product candidate is a ready-to-infuse autologous T-cell therapy
utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of
patients with Stage IV metastatic melanoma, and is based on a clinical
CRADA with the National Cancer Institute along with physician-sponsored
investigational therapy at the MD Anderson Cancer Center and the H. Lee
Moffitt Cancer & Research Institute. For more information, please visit http://www.lionbio.com.
Source: Lion Biotechnologies, Inc.